ライフサイエンスコーパス: phentermine

1 f 25 h after intake of a single oral dose of phentermine.

2 te suppressants or among those who took only phentermine.

3 .9 to 87.1) with the use of fenfluramine and phentermine.

4 5 mg plus topiramate 46.0 mg, and 73 (7%) to phentermine 15.0 mg plus topiramate 92.0 mg had depressi

5 .5 mg plus topiramate 46.0 mg, or once-daily phentermine 15.0 mg plus topiramate 92.0 mg in a 2:1:2 r

6 ntermine 7.5 mg plus topiramate 46.0 mg, and phentermine 15.0 mg plus topiramate 92.0 mg, respectivel

7 ntermine 7.5 mg plus topiramate 46.0 mg, and phentermine 15.0 mg plus topiramate 92.0 mg, respectivel

8 e 7.5 mg plus topiramate 46.0 mg, and 995 to phentermine 15.0 mg plus topiramate 92.0 mg; 979, 488, a

9 d 687 (70%; 9.0, 7.3 to 11.1; p<0.0001) with phentermine 15.0 mg plus topiramate 92.0 mg; for >/=10%

10 ugs in combination (fenfluramine 1 mg/kg and phentermine 2 mg/kg) amplified the effects of each, incr

11 Phentermine (2 mg/kg, i.p.), on the other hand, signific

12 randomly assigned treatment [placebo, 7.5 mg phentermine/46 mg controlled-release topiramate (7.5/46)

13 ratio 6.3, 95% CI 4.9 to 8.0; p<0.0001) with phentermine 7.5 mg plus topiramate 46.0 mg, and 687 (70%

14 4%) patients assigned to placebo, 19 (4%) to phentermine 7.5 mg plus topiramate 46.0 mg, and 73 (7%)

15 tients, 994 were assigned to placebo, 498 to phentermine 7.5 mg plus topiramate 46.0 mg, and 995 to p

16 0.0001) in the patients assigned to placebo, phentermine 7.5 mg plus topiramate 46.0 mg, and phenterm

17 207 [21%] in the groups assigned to placebo, phentermine 7.5 mg plus topiramate 46.0 mg, and phenterm

18 or abdominal obesity) to placebo, once-daily phentermine 7.5 mg plus topiramate 46.0 mg, or once-dail

19 rolled-release topiramate (7.5/46), or 15 mg phentermine/92 mg controlled-release topiramate (15/92)]

20 nterval, 0 to 15.4) and among those who took phentermine alone (95 percent confidence interval, 0 to

21 r chronic administration of fenfluramine and phentermine, alone or in combination, on brain dopamine

22 ned 1163 patients who had taken fenfluramine-phentermine and 672 control patients who had not taken t

23 A recent meta-analysis of phentermine and diethylpropion reported pooled mean diff

24 Coadministration of phentermine and fenfluramine (phen/fen) effectively trea

25 en the length of treatment with fenfluramine-phentermine and the prevalence of valvular abnormalities

26 The combination of phentermine and topiramate caused significant weight los

27 placebo-controlled trial of extended-release phentermine and topiramate in 24 patients to validate as

28 d calorie intake; weight loss in response to phentermine and topiramate was significantly associated

29 The combination of phentermine and topiramate, with office-based lifestyle

30 o 102.2) with the use of dexfenfluramine and phentermine, and 26.3 (7.9 to 87.1) with the use of fenf

31 Up-to-date meta-analyses of sibutramine, phentermine, and diethylpropion were identified.

32 e, 3,4-methylenedioxymethamphetamine (MDMA), phentermine, and mephedrone) in one method using their c

33 phetamine, methamphetamine, amphetamine, and phentermine, as well as a non-amphetamine releaser, 4-be

34 % CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease.

35 Obese patients who took fenfluramine and phentermine, dexfenfluramine alone, or dexfenfluramine a

36 ns in the United States for fenfluramine and phentermine exceeded 18 million.

37 when the off-label use of fenfluramine plus phentermine (fen-phen) and the approval of dexfenflurami

38 valvulopathy associated with treatment with phentermine, fenfluramine, and dexfenfluramine is now be

39 estigation sought to determine the effect of phentermine-fenfluramine (phen-fen) on the prevalence of

40 th the appetite-suppressant drugs, including phentermine-fenfluramine.

41 ence interval [CI], 1.32-3.59), 13.7% in the phentermine/fenfluramine group (RR, 3.34; 95% CI, 2.09-5

42 (10.4) months (range, 1.4-63 months) in the phentermine/fenfluramine group, while the untreated grou

43 ata indicate that use of dexfenfluramine and phentermine/fenfluramine is associated with an increase

44 ] had increases; P<.001 vs controls); and 15 phentermine/fenfluramine patients (4.5% all decreases; P

45 7.5 months (range, 13-26 months) and for 340 phentermine/fenfluramine patients was 18.7 months (range

46 atment were uncommon (dexfenfluramine, 2.3%; phentermine/fenfluramine, 2.4%, and untreated, 3.3%, whe

47 d untreated subjects (dexfenfluramine, 9.0%; phentermine/fenfluramine, 4.0%; and untreated, 8.4%); an

48 e (479 and 455 had taken dexfenfluramine and phentermine/fenfluramine, respectively, continuously for

49 after discontinuation of dexfenfluramine and phentermine/fenfluramine.

50 The negative control drugs were phentermine, fluoxetine, its metabolite norfluoxetine, a

51 uramine and phentermine, or fenfluramine and phentermine for various periods.

52 exfenfluramine alone, or dexfenfluramine and phentermine had a significantly higher prevalence of car

53 compounds diethylpropion, fenfluramine, and phentermine had no effect on K(ATP) channel activity in

54 fluramine, usually given in combination with phentermine, has been reported to be associated with car

55 Fenfluramine and phentermine have been individually approved as anorectic

56 pressants fenfluramine, dexfenfluramine, and phentermine have been used alone or in combination as an

57 Topiramate (Topamax) and phentermine have long been approved in the United States

58 te and the antiobesity medications orlistat, phentermine hydrochloride, and sibutramine hydrochloride

59 f the appetite suppressants fenfluramine and phentermine is associated with an increased risk of card

60 codeine, heroine, methamphetamine, morphine, phentermine, L-phenylepherine, proglitazone, and rosigli

61 n dexfenfluramine alone, dexfenfluramine and phentermine, or fenfluramine and phentermine for various

62 ssed the efficacy and safety of two doses of phentermine plus topiramate controlled-release combinati

63 and lorcaserin to 9% for top-dose (15/92 mg) phentermine plus topiramate-extended release at 1 year.

64 3% for orlistat, and 67% to 70% for top-dose phentermine plus topiramate-extended release.

65 ormalities in patients who took fenfluramine-phentermine primarily involve those who had taken these

66 Sibutramine, orlistat, phentermine, probably diethylpropion, bupropion, probabl

67 These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular hear

68 Candidates for fenfluramine-phentermine therapy should be informed about serious pot

69 tion between these features and fenfluramine-phentermine therapy.

70 months after the initiation of fenfluramine-phentermine therapy.

71 received fenfluramine, and 862 who received phentermine to assess the risk of a subsequent clinical

72 5% weight loss vs 75% of participants taking phentermine-topiramate (odds ratio [OR], 9.22; 95% credi

73 Phentermine-topiramate and liraglutide were associated w

74 weight loss compared with placebo at 1 year-phentermine-topiramate, 8.8 kg (95% CrI, -10.20 to -7.42

75 orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide, compared with p

76 Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to l

77 and liraglutide; in the USA, lorcaserin and phentermine/topiramate are also available.

78 Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been rec

79 t 6 months of 3.6 kg (CI, 0.6 to 6.0 kg) for phentermine-treated patients and 3.0 kg (CI, -1.6 to 11.

80 The combination of fenfluramine and phentermine was a widely used obesity treatment before t

81 A pharmacokinetic curve for the incurred phentermine was successfully produced using the describe

82 isease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease.

83 erin and the extended release combination of phentermine with topiramate have recently gained approva